Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Sep 4, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed registered initial public offering of the Company’s ordinary shares, to be delivered in the form of American Depositary Shares (“ADSs”), in the United States, as well as a concurrent private placement of ordinary shares (together with the ADSs, the "Securities") to certain qualified investors in Europe. The number and price of the Securities to be sold in the offering has not yet been determined.
Orphazyme files registration statement
Read moreCapital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Sep 1, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 1,927 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Capital increase of 1 927 shares in Orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Sep 1, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S
Aug 28, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced.
Read moreOrphazyme announces Interim Report First Half 2020
Aug 28, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces its Interim Report First Half 2020 for the period January 1–June 30, 2020.
Orphazyme announces interim report first half 2020
Read moreOrphazyme Interim Report First Half 2020 Presentation
Aug 26, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Interim Report First Half 2020. The presentation will be followed by a Q&A session.
Orphazyme interim report first half 2020
Read moreCapital increase of 31,250 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Jul 31, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Protein in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the vesting and exercise of Matching Shares. A total of 31,250 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Matching Share of DKK 1.
Capital increase of 31 250 shares in orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 29, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreOrphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C
Jul 20, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme completes rolling submission of new drug
Read moreOrphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research
Jul 17, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that it will join The Michael J. Fox Foundation’s (MJFF) Parkinson’s Disease Research Tools Consortium. The group brings together experts from the medical community and industry to identify and develop new pre-clinical tools to address unmet research needs and accelerate experiments. Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).
Orphazyme to collaborate with the Michael J. Fox foundation
Read more